BACKGROUND: Levels of the pro-tumorigenic prostaglandin PGE 2 are increased in colorectal cancer, previously attributed to increased synthesis through COX-2 upregulation and, more recently, to decreased catabolism. The functionally linked genes 15-prostaglandin dehydrogenase (15-PGDH) and the prostaglandin transporter PGT co-operate in prostaglandin degradation and are downregulated in colorectal cancer. We previously reported repression of 15-PGDH expression by the Wnt/b-catenin pathway, commonly deregulated during early colorectal neoplasia. Here we asked whether b-catenin also regulates PGT expression. and Rothwell, 2012; Rothwell et al, 2012a, b) have reinforced interest in the potential value of using NSAIDs, such as aspirin, in colorectal cancer chemoprevention. Over much of the last few decades, a major focus of colorectal cancer chemoprevention has been inhibition of COX-2, an inducible cyclooxygenase isoform that is upregulated at the medium/large adenoma stage, and to which the elevated levels of the protumorigenic prostaglandin PGE 2 have previously been attributed (Rigas et al, 1993; Eberhart et al, 1994; Elder et al, 2002) . However, several lines of evidence suggest a potential role for COX-1 in colorectal neoplasia. For example, tumorigenesis in animal models can be suppressed by deletion of either COX-1 or COX-2 genes (Chulada et al, 2000) , or by administration of a COX-1-selective inhibitor (Kitamura et al, 2002) , though the precise role of COX-1 in intestinal neoplasia is unclear. Our recent paper in Gut (Smartt et al, 2012) highlighted a mechanism by which COX-1 could contribute to early colorectal cancer development. We showed that b-catenin, activated at the earliest stages of colorectal neoplasia, can repress expression of the colorectal tumour suppressor and prostaglandin catabolising enzyme 15-prostaglandin dehydrogenase (15-PGDH). Here, we now show that b-catenin also represses expression of a second gene crucial for prostaglandin catabolism, the prostaglandin transporter PGT. PGT (aka SLCO2A1) mediates uptake of secreted prostaglandins, enabling their oxidative inactivation by cytoplasmic 15-PGDH (Nomura et al, 2004) . Like 15-PGDH, downregulation of PGT has been reported in both human colorectal tumours and in pre-malignant adenomas in APC min/ þ mice, and this was suggested to result, at least in part, from epigenetic silencing (Holla et al, 2008) . However, we hypothesised that b-catenin may also have a role in repression of PGT expression in colorectal cancer, as we reported previously for 15-PGDH. Here we show that modulating b-catenin expression or function increases PGT expression, both in the intestinal epithelium in vivo, and in colorectal adenoma and carcinoma cells in vitro. Our data suggest that b-catenin co-ordinately regulates prostaglandin turnover through the
Recent studies in the Lancet (Algra and Rothwell, 2012; Rothwell et al, 2012a, b) have reinforced interest in the potential value of using NSAIDs, such as aspirin, in colorectal cancer chemoprevention. Over much of the last few decades, a major focus of colorectal cancer chemoprevention has been inhibition of COX-2, an inducible cyclooxygenase isoform that is upregulated at the medium/large adenoma stage, and to which the elevated levels of the protumorigenic prostaglandin PGE 2 have previously been attributed (Rigas et al, 1993; Eberhart et al, 1994; Elder et al, 2002) . However, several lines of evidence suggest a potential role for COX-1 in colorectal neoplasia. For example, tumorigenesis in animal models can be suppressed by deletion of either COX-1 or COX-2 genes (Chulada et al, 2000) , or by administration of a COX-1-selective inhibitor (Kitamura et al, 2002) , though the precise role of COX-1 in intestinal neoplasia is unclear. Our recent paper in Gut (Smartt et al, 2012) highlighted a mechanism by which COX-1 could contribute to early colorectal cancer development. We showed that b-catenin, activated at the earliest stages of colorectal neoplasia, can repress expression of the colorectal tumour suppressor and prostaglandin catabolising enzyme 15-prostaglandin dehydrogenase (15-PGDH). Here, we now show that b-catenin also represses expression of a second gene crucial for prostaglandin catabolism, the prostaglandin transporter PGT. PGT (aka SLCO2A1) mediates uptake of secreted prostaglandins, enabling their oxidative inactivation by cytoplasmic 15-PGDH (Nomura et al, 2004) . Like 15-PGDH, downregulation of PGT has been reported in both human colorectal tumours and in pre-malignant adenomas in APC min/ þ mice, and this was suggested to result, at least in part, from epigenetic silencing (Holla et al, 2008) . However, we hypothesised that b-catenin may also have a role in repression of PGT expression in colorectal cancer, as we reported previously for 15-PGDH. Here we show that modulating b-catenin expression or function increases PGT expression, both in the intestinal epithelium in vivo, and in colorectal adenoma and carcinoma cells in vitro. Our data suggest that b-catenin co-ordinately regulates prostaglandin turnover through the negative regulation of both PGT and 15-PGDH expression, and highlight a potential mechanism that could contribute to the chemopreventive efficacy of the non-selective NSAID aspirin.
MATERIALS AND METHODS
The colon carcinoma-derived cell lines HCT15, HCT116, HT29, LOVO, LS174T, SW480 and SW620, obtained from the American Type Culture Collection (Rockville, MD, USA); the HCA7 colony 29 (HCA7) colon carcinoma cell line, a kind gift of Susan Kirkland (Kirkland, 1985) ; the dox-inducible dnTCF4-expressing LS174T/ dnTCF4 cell line, a kind gift from Hans Clevers ; and colon adenoma-derived cell lines PC/AA/C1, PC/ AA/C1/SB10C, PC/BH/C1, S/AN/C1 and S/RG/C2 derived in this laboratory (Paraskeva et al, 1984 (Paraskeva et al, , 1989 Williams et al, 1990) were maintained as described previously (Paraskeva et al, 1984; Moore et al, 2009) , except for PC/AA/C1 and PC/AA/C1/SB10C, which were maintained on conditioned medium (Williams et al, 1990) . Immunohistochemical staining using a rabbit polyclonal PGT antibody (kind gift of Michel Fortier, Quebec, Canada) and inducible intestinal b-catenin ablation in mice were carried out and validated as previously described (Smartt et al, 2012) , as was intestinal epithelial cell fractionation (see also Mariadason et al, 2005) . RNA interference, immunoblotting and mRNA preparation were also performed as previously described (Smartt et al, 2012) . Semi-quantitative RT-PCR was carried out as in Chell et al (2006) , with minor modifications, and quantitative real-time RT-PCR was carried out as described previously (Moore et al, 2009 ), using PGT primers from Qiagen (Crawley, West Sussex, UK).
RESULTS
Preliminary studies suggested that, similar to 15-PGDH, PGT also shows an expression gradient in the human intestinal epithelium, being highest in the differentiated luminal/villus compartment ( Figure 1A) . A similar PGT expression gradient was also observed in the murine small intestinal epithelium, both at the mRNA ( Figure 1B ) and protein level ( Figure 1C ). As Wnt/b-catenin transcriptional activity is known to be highest in the proliferative crypt compartment Kosinski et al, 2007) , we hypothesised that PGT may also be repressed by b-catenin in intestinal epithelial cells. Importantly, the gradient of PGT expression was lost following inducible b-catenin ablation ( Figure 1D ; Fevr et al, 2007) . Elevated PGT expression was particularly noticeable in crypt epithelia (compare Figure 1F with E) , where b-catenin activity is normally highest van de Wetering et al, 2002) . This increase is consistent with previously published microarray analysis (1.67-fold increase, Fevr et al, 2007) , confirming that b-catenin represses PGT expression in the normal murine intestinal epithelium.
We then hypothesised that b-catenin may also repress PGT expression in human colorectal cancer cells, as is the case for 15-PGDH. Indeed, in line with this hypothesis, basal PGT levels are reportedly very low to undetectable in most colorectal carcinoma cell lines (Holla et al, 2008) . We confirmed and extended this observation to include cell lines derived from sporadic (S/RG/C2, S/AN/C1) and familial adenomatous polyposis patient (PC/AA/C1, PC/BH/C1) adenomas and one in-vitro-transformed adenoma cell line (PC/AA/C1/SB10C) (Figure 2A ). Indeed, in our hands, PGT mRNA was only readily detectable in LoVo carcinoma-derived and PC/BH/C1 adenoma-derived cells under basal conditions. Notably, siRNA-mediated knockdown of b-catenin increased PGT mRNA expression in both adenoma-and carcinoma-derived cell lines ( Figure 2B and C) . In addition, PGT mRNA levels were consistently increased in the colorectal carcinoma cell line LS174T/dnTCF4, 48 h following induction of dnTCF4, a dominant-negative form of this b-catenin-binding partner that is unable to bind b-catenin ( Figure 2D and E). Hence, taken together, these data suggest that b-catenin represses PGT expression in both the normal intestinal epithelium and in colorectal cancer.
DISCUSSION
In this article, we have identified a novel link between two important pathways in colorectal neoplasia, Wnt/b-catenin and PGE 2 signalling, through the negative regulation of PGT expression. Therefore, similar to 15-PGDH, PGT expression could be widely downregulated at a very early stage of colorectal neoplasia in sporadic tumours as well as those arising in the context of a b-catenin represses PGT expression in colorectal cancer HJM Smartt et al germline APC mutation. Downregulation of PGT, in addition to 15-PGDH, may constitute a very effective means of increasing local PGE 2 levels as impaired PGT-mediated prostaglandin import would be expected to directly increase extracellular prostaglandin concentrations available to interact with cell surface receptors.
The ability of b-catenin to downregulate both 15-PGDH and PGT, two crucial regulators of prostaglandin catabolism, points towards the importance of elevated COX-1-derived prostaglandin levels during early colorectal neoplasia before COX-2 upregulation, and may go some way to explain the particular efficacy in colorectal cancer chemoprevention of the non-selective NSAID aspirin. 
